October 10, 2026
Sage Therapeutics is restructuring yet again, announcing Thursday a company shakeup that will involve layoffs for about one-third of its
Clinical trial results released by Wave Life Sciences Wednesday appear to provide early validation for the company’s newest drugmaking technology
Dive Brief: The Food and Drug Administration on Tuesday approved a new device to treat non-small cell lung cancer, Novocure’s
Dive Brief: Sales of Johnson & Johnson’s cancer therapy Carvykti and immune disease drug Tremfya grew strongly during the third
Dive Brief: European life sciences venture firm Forbion on Tuesday said it has raised 2 billion euros, or more than
Danish drugmaker Lundbeck has agreed to spend $2.6 billion acquiring a young biotechnology company with an experimental brain medicine that
The Food and Drug Administration has temporarily deflected a lawsuit alleging it violated federal law by removing Eli Lilly’s obesity
An effective launch sets the stage for a new drug’s long-term success. It shapes provider and patient perceptions, drives medication
The number of medical devices with artificial intelligence technology has risen sharply in the past decade. The Food and Drug
Two former Pfizer executives announced late Wednesday night that they won’t support efforts by activist investor Starboard Value to shake
Dive Brief: Upstream Bio announced Thursday it priced its initial public offering, raising $255 million to fund development of an antibody
Today, a brief rundown of news from Roche and Turnstone Biologics, as well as updates from Sanofi, Pfizer and Flagship
For the past year, French pharmaceutical giant Sanofi has been searching for a buyer to take control of its consumer
Dive Brief: Upstream Bio announced Thursday it priced its initial public offering, raising $255 million to fund development of an antibody
Dive Brief: UnitedHealth Group and CVS Health want Federal Trade Commission Chair Lina Khan and two other commissioners to recuse
Dive Brief: Eli Lilly and Insitro said they have entered into three drug development deals that offer a “new paradigm”
Biotechnology company Purespring Therapeutics has raised about $105 million to fund its development of gene therapies for diseases of the
Basecamp Research, a biotechnology startup focused on artificial intelligence, has raised $60 million in funding and signed a multi-year collaboration
Alzheimer’s disease remains one of the world’s most indomitable illnesses, and on Tuesday it defeated yet another potential treatment in
Dive Brief: An experimental, muscle-preserving therapy from Scholar Rock succeeded in a Phase 3 trial in spinal muscular atrophy, positioning
Dive Brief: GSK-backed ViiV Healthcare on Monday said it plans to triple the amount of its HIV prevention therapy it
In developing drugs for rare diseases, ensuring long-term patient safety is paramount. Unlike more common conditions, rare diseases present unique challenges
Dive Brief: A major California health plan has struck a novel deal with a drug manufacturer for a cheaper version
Cassava Sciences has faced intense regulatory scrutiny over alleged clinical impropriety in studies of its experimental Alzheimer’s disease drug. Most
Today, a brief rundown of news from Bristol Myers Squibb and Johnson & Johnson, as well as updates from Bayer,
Over the past decade, the medicine Enjaymo has been passed around no less than five times by developers large and
Dive Brief: Gene editing company Editas Medicines has sold off license fees and future payments it’s owed under an agreement
Dive Brief: Shortages affecting the availability of Eli Lilly’s top-selling diabetes and weight-loss drugs have now been resolved, the Food
The U.S. government is fine-tuning the rules for how it will negotiate drug prices within Medicare when the second round
Dive Brief: Eli Lilly on Wednesday announced plans to spend $4.5 billion on a new facility that will use advancements
Dive Brief: Gilead on Wednesday said it signed royalty-free licensing agreements with six generic drugmakers to produce and sell its
Today, a brief rundown of news from IGM Biosciences and Metsera, as well as updates from Gritstone Bio, UCB and
With rare exceptions, biotechnology and pharmaceutical companies validate their business plans through clinical trials, results from which are often presented
Boston-based Aktis Oncology has raised $175 million in fresh funding to advance its pipeline of radiopharmaceutical medicines for cancer. The
Dive Brief: Roche on Monday agreed to pay $850 million to acquire two experimental breast cancer drugs being developed by
Precision oncology continues to be one of the fastest-growing markets within pharmaceuticals. Valued at $130 Billion in 2023, the global
2Seventy bio, the cancer-focused drugmaker spun out of Bluebird bio, has decided to stop enrolling a key study that’s been
Arch Venture Partners, a prominent creator of biotechnology startups, has raised more than $3 billion for its 13th fund, the
Dive Brief: Two House Democrats have called for an investigation of former Food and Drug Administration device director Jeff Shuren
The Food and Drug Administration on Friday approved Regeneron Pharmaceuticals and Sanofi’s inflammatory disease drug Dupixent for a common lung
Today, a brief rundown of news from J&J and the FDA, as well as updates from Sage Therapeutics, Roche and
For the first time in more than two decades, a completely new form of antipsychotic medication will be available in
Dive Brief: Pfizer is pulling the sickle cell disease drug Oxbryta off the market and ending clinical trials of the
BioAge Labs has raised $198 million in an initial public offering, the company announced Wednesday, capitalizing on intense investor interest
Genespire, an Italy-based biotechnology startup making “off-the-shelf” gene therapies treatment for rare pediatric genetic conditions, has raised €46.6 million euros,
Novo Nordisk’s top executive vowed to reopen price negotiations with insurers covering the company’s obesity and diabetes drugs at a
Struggling gene therapy developer Bluebird bio is again cutting costs, announcing Tuesday a plan to lay off about a quarter
After more than two decades of work, partners Biogen and UCB say they finally have positive results from a late-stage
Dive Brief: An experimental medicine from AstraZeneca and Daiichi Sankyo failed to help people with a common form of breast
Dive Brief: Vicebio, a London-based biotechnology startup, has raised $100 million in Series B financing to continue developing a technology
A new company born out of research done by top Harvard genetic scientist George Church is promising to “revolutionize cell
Dive Brief: 23andMe’s independent board directors resigned on Tuesday amid uncertainty about the DNA testing company’s future. In a letter
European drug regulators have officially turned back a first-of-its-kind eye drug from Apellis Pharmaceuticals despite multiple attempts by the company
Dive Brief: The Federal Trade Commission has filed suit against the three largest pharmacy benefit managers in the country for
Today, a brief rundown of news from Sanofi and Novo Nordisk, as well as updates from The Lasker Foundation, Edgewise
Dive Brief: Roche’s antiviral drug Xofluza reduced influenza transmission among household contacts in a large Phase 3 study, the company
Dive Brief: People with a common form of macular degeneration needed far fewer injections to manage their eye condition following
Dive Brief: Organon has agreed to buy Roivant’s dermatology subsidiary Dermavant for $175 million upfront plus more than $1 billion
Today, a brief rundown of news from Novartis and GSK, as well as updates from Omega Funds, Serán Bioscience and
BioMarin Pharmaceutical, after months of layoffs, spending cuts and research reorganizations, has staked its future on the continued success of its
Dive Brief: An antibody-drug conjugate developed by Daiichi Sankyo and Merck & Co. met the main goal of a Phase
Sanofi said it’s ready to meet demand for its RSV shot Beyfortus this year, announcing Monday the clearance by the
Over the weekend at the European Society for Medical Oncology’s annual meeting in Barcelona, cancer researchers unveiled results from scores
Listen to the article 4 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief:
A decade of follow-up on people with melanoma who were treated with cancer immunotherapy shows how two drugs have dramatically
Vironexis Biotherapeutics emerged from stealth with plans to start what it claims will be the first-ever clinical trial testing a
Small biotechnology company iTeos Therapeutics could succeed where larger drugmakers have fallen short, should study results it presented Saturday at
Today, a brief rundown of news from Roche and Gilead Sciences, as well as updates from Eli Lilly, Biogen and
Months after winning approval of a new vaccine for respiratory syncytial virus, Moderna is acknowledging that wresting market share from
Three drug startups collectively raised more than $700 million in initial public offerings Thursday, a flurry of activity after a
Dive Brief: An experimental drug Fulcrum Therapeutics has been testing against a type of muscular dystrophy failed a Phase 3
Dive Brief: Sanofi and Regeneron plan to make a second attempt at expanding use of their blockbuster drug Dupixent to
Dive Brief: BridgeBio Pharma plans to trim its spending on gene therapy research by more than $50 million after early-stage
Early results from a small study have convinced Centessa Pharmaceuticals to “rapidly advance” an experimental drug it believes could be
Bain Capital Life Sciences said Tuesday it has secured about $3 billion for its fourth fund, bringing the private investment
Dive Brief: An experimental weight loss pill developed by biotechnology company Terns Pharmaceuticals helped some people with obesity lose more
Dive Brief: An experimental drug regimen for breast cancer being developed by Relay Therapeutics delayed tumor growth by a median
Nine years ago, Lisa Haines got news no one wants to hear. Her doctors said her lung cancer, which chemotherapy
An experimental medicine from a small biotechnology company cut the risk of lung cancer progression in half when tested against
Dive Brief: Novartis said Wednesday it’s expanding a manufacturing site in Indianapolis and building a new plant in California in
Dive Brief: GSK on Friday said its Nucala medicine succeeded in a Phase 3 study of patients with chronic obstructive
Today, a brief rundown of news from OrsoBio, as well as updates from Boehringer Ingelheim, Novartis and Vaxcyte that you
Dive Brief: A Delaware judge ruled Wednesday that Johnson & Johnson must pay Auris Health’s former investors more than $1
The CEO of Lykos Therapeutics will step down after the company’s efforts to win a milestone approval for MDMA as
Eli Lilly on Thursday revealed new data that could help it catch rival Novo Nordisk in a race between the
BioMarin Pharmaceutical has brought eight rare disease drugs to market over the past 25 years, a record few companies in
Today, a brief rundown of news from Biogen, as well as updates from Dyne Therapeutics, Denali Therapeutics and Novo Nordisk
Dive Brief: Shares in vaccine developer Vaxcyte soared by over 35% Tuesday after the company unveiled results from a large
Regulators in the U.S. and Europe recently determined that a popular group of drugs for weight loss and diabetes don’t
The psychedelic drug field hit a setback this month when the Food and Drug Administration rejected Lykos Therapeutics’ application for
The chair of the powerful House Committee on Oversight and Accountability is threatening the leaders of the three largest pharmacy
Investment in developers of cell and gene therapies has nosedived this year, a sharp drop-off that investors and analysts say
Johnson & Johnson is asking the Food and Drug Administration to approve a new medicine the company believes can eventually
Two months ago, Alnylam Pharmaceuticals revealed that a medicine it’s been developing for people with a deadly heart condition succeeded
Today, a brief rundown of news from Novo Nordisk and Ventyx Biosciences, as well as updates from Novartis and Pfizer
Dive Brief: Merck & Co.’s drug Keytruda failed to help people with cancer in two clinical trials, both using the
Amid a major corporate shakeout, BioMarin Pharmaceutical intends to lay off over 200 staff, according to a regulatory filing made
Bayer and biotechnology company NextRNA Therapeutics on Wednesday said they have partnered to develop a new kind of small molecule
Neurocrine Biosciences on Wednesday reported results from a schizophrenia drug study that, despite one bright spot, mostly disappointed investors. The
Dive Brief: Eli Lilly is now distributing a single-dose vial form of its popular weight loss medicine Zepbound that it
Pfizer on Tuesday launched a direct-to-consumer service it claims will help people schedule telehealth appointments, fill prescriptions and access savings
Genetic medicines startup Tome Biosciences is letting go of much of its staff after hitting setbacks following a buzzy launch
Dive Brief: The European Commission has authorized Regeneron’s dual-acting drug odronextamab to treat two types of lymphoma, clearing it for
Large employers are bracing for a substantial increase in healthcare costs next year, driven by higher spending on medicines like
Listen to the article 4 min This audio is auto-generated. Please let us know if you have feedback. BioMarin is
Chinook Therapeutics ranks among Versant Ventures’ most successful biotechnology bets. The kidney disease drug developer, which Versant founded in 2019
The Food and Drug Administration is defending the record of Jeff Shuren, former director of the agency’s medical device center,
Dive Brief: A pair of U.S. biotechnology companies on Thursday filed plans for initial public offerings, testing a market that’s
Listen to the article 4 min This audio is auto-generated. Please let us know if you have feedback. Today, a
Dive Brief: The Food and Drug Administration on Thursday cleared new versions of Pfizer’s and Moderna’s COVID-19 vaccines that are
Leqembi’s benefits are “too small to justify the significant cost to the NHS,” said the head of a UK agency
BridgeBio Pharma has transferred several preclinical and early clinical-stage drugs to a new company, GondolaBio, that’s drawn $300 million in
Dive Brief: After warning investors earlier this month of a possible delay, Regeneron Pharmaceuticals on Tuesday confirmed that U.S. regulators
Dive Brief: The Food and Drug Administration has approved a new combination drug regimen from Johnson & Johnson to treat
Dive Brief: Weekly injections of tirzepatide, the drug Eli Lilly sells as Mounjaro and Zepbound, substantially lowered the likelihood people
BioNTech partner MediLink Therapeutics can resume enrollment of a Phase 1 clinical trial testing an antibody-drug conjugate in people with
Bristol Myers Squibb’s highly anticipated schizophrenia drug KarXT is fast approaching a September deadline for the Food and Drug Administration
The U.S. government on Thursday said it stands to save taxpayers $6 billion on the prices it will pay for
The Food and Drug Administration has approved another medicine for a rare condition that arises after a bone marrow or
The Biden administration struck a triumphant tone on Thursday in rolling out the first drug price cuts negotiated by Medicare,
Dive Brief: Pfizer and BioNTech on Friday said a combination flu and COVID-19 shot they’ve been developing met one of
Today, a brief rundown of news from Zealand Pharma and Bluebird Bio, as well as updates from Boundless Bio and
Lykos Therapeutics plans to lay off about 75% of its staff as part of a larger shake-up at the California-based
Dive Brief: Gilead Sciences has won Food and Drug Administration approval to sell Livdelzi, a new medicine for a rare
Dive Brief: Grail said it will lay off about 350 employees in a restructuring that comes less than two months
Dive Brief: Evotec, a German drug discovery and contract development and manufacturing company, is restructuring amid a slowdown in early-stage
Dive Brief: Acelyrin, the biotechnology company behind the sector’s largest initial public offering last year, is shifting away from the
Dive Brief: Pfizer on Monday said its RSV vaccine Abrysvo led to strong immune responses in immunocompromised adults given the
A day after the Food and Drug Administration rejected MDMA as a therapy aid for post-traumatic stress disorder, a scientific
Dive Brief: Eli Lilly on Tuesday raised its revenue forecast for the year by $3 billion as it reported second-quarter
Dive Brief: Recursion and Exscientia, two artificial intelligence firms, on Thursday announced that they would combine, betting their complementary skills
Dive Brief: Treatment with an Apellis Pharmaceuticals drug appeared to benefit people with one of two uncommon kidney diseases, according
Eli Lilly is making progress resolving the supply strains that for months have made its in-demand obesity and diabetes medicines
The recent downturn in the biotechnology sector affected startups in many ways, from the availability of financing to the types
The Food and Drug Administration has rejected a bid to get MDMA approved as a therapy aid for people with
Merck & Co. on Friday acquired an experimental drug designed to wipe out the immune system’s B cells in a
Today, a brief rundown of news from Merck & Co. and Cabaletta Bio, as well as updates from Intellia Therapeutics,
Dive Brief: Sarepta Therapeutics’ yearly financial outlook and quarterly earnings, including sales of Elevidys, its gene therapy for Duchenne muscular
Today, a brief rundown of news from Amgen and Servier, as well as updates from Merck & Co., Precigen and
Dive Brief: The first medicine approved for a liver disease known as MASH is off to a faster launch than
Despite decades of research and many millions of dollars invested, Roche still has yet to develop a drug that works
Venture firm Apple Tree Partners has invested $55 million in a new biotechnology company developing antiviral treatments capable of working
Dive Brief: All doses of tirzepatide, the drug Eli Lilly sells as Zepbound for obesity and Mounjaro for diabetes, are
For years, many manufacturers have assumed that pre-market physician education was not strictly necessary unless their brand was the first
Dive Brief: Cigna’s chief executive is pledging to be more aggressive in defending its pharmacy benefit manager amid mounting public
Shares of Moderna fell nearly 20% on Thursday after the company lowered its 2024 financial forecasts amid slowing sales and
Eli Lilly’s tirzepatide, the in-demand drug sold as Zepbound for weight loss, has for the first time been shown in
Today, a brief rundown of news from Vir Biotechnology and Vertex Pharmaceuticals, as well as updates from Neurocrine Biosciences, Alnylam
The Food and Drug Administration on Thursday approved a new type of cellular medicine, clearing a therapy developed by the
Prominent gene therapy researcher Jim Wilson will depart the University of Pennsylvania, where he led one of the field’s largest
Dive Brief: Gene therapy developer UniQure will shrink its workforce by 65%, cutting 300 roles across the company alongside the
Today, a brief rundown of news from Vertex Pharmaceuticals and Merck & Co. as well as updates from Fibrogen, Intellia
Dive Brief: GSK on Wednesday lowered its forecast for vaccine sales this year, citing inventory changes and shifting retail prioritization
Dive Brief: RNA editing startup Airna is adding more funds to its Series A round, raising another $60 million as
Pfizer missed its first chance at following Novo Nordisk and Eli Lilly into the fast-growing market for GLP-1 obesity drugs.
Dive Brief: GSK is the latest pharmaceutical company to form a drug-hunting partnership with Flagship Pioneering, announcing Monday a deal
After a dramatic post-pandemic downturn, a sense of stabilization has returned to biotech, and more healthcare professionals feel optimistic about
Today, a brief rundown of news from Dren Bio and Geron as well as updates from Moderna, Brenig Therapeutics and
Viking Therapeutics shares soared by more than 30% early Thursday after the company told investors it’s moving an experimental obesity
Dive Brief: Sen. Elizabeth Warren, D-Mass., introduced legislation that would reverse the Supreme Court’s recent ruling on the Chevron doctrine,
A key regulatory committee that influences whether new drugs enter the European market has voted against Leqembi, Eisai and Biogen’s
Today, a brief rundown of news from AbbVie and AstraZeneca as well as updates from Glycomimetics, Cue Biopharma and Confo
Bristol Myers Squibb on Friday raised its forecast for revenue and profit per share this year after a second quarter
Shares of French pharmaceutical giant Sanofi ticked up Thursday morning with the release of an earnings report that beat Wall
Roche is best known for the cancer drugs that still account for much of its drug revenue. But the Swiss
Dive Brief: An experimental gene therapy from Pfizer succeeded in a Phase 3 study of people with hemophilia A, overcoming
In 2020, Biogen wagered more than $1 billion on two experimental drugs developed in the labs of Sage Therapeutics, a
Dive Brief: A two-year-old biotechnology startup led by former Johnson & Johnson executives has raised $165 million to develop “multifunctional”
Dive Brief: An experimental Merck & Co. drug designed to protect infants from illness caused by respiratory syncytial virus succeeded
Ionis Pharmaceuticals plans to push one of its rare disease drugs into late-stage testing now that a smaller trial has
The U.S. government will not give Bluebird bio a green light to offer fertility support to federally insured people undergoing
Recent advancements in immune checkpoint inhibitors (ICIs) targeting PD-1 or CTLA4 have shown significant success in treating various advanced cancers
Dive Brief: Gilead chief medical officer Merdad Parsey will step down from his role and leave the biotechnology company early
Today, a brief rundown of news from Caribou Sciences and Relay Therapeutics as well as updates from Corden Pharma, Celldex
Dive Brief: A closely watched obesity pill being developed by Roche helped people in a small Phase 1 trial lose
Today, a brief rundown of news from Morphic Holding as well as updates from Novartis, the Parker Institute and Agenus
Cybersecurity firm CrowdStrike triggered a massive IT outage on Friday, disrupting businesses, including healthcare, after issuing what was supposed to be a
Boehringer Ingelheim will sell an unbranded version of its Humira biosimilar at a 92% discount to the list price of
Dive Brief: Artiva Biotherapeutics on Thursday raised $167 million in an initial public offering centered around the promise of donor-derived cell
Dive Brief: Sales of Johnson & Johnson’s depression drug Spravato accelerated in the second quarter, putting the medicine on pace
Medical device companies have been steadily cutting jobs for the past 18 months, eliminating thousands of positions as firms look
Dive Brief: NGM Biopharmaceuticals, which was taken private earlier this year, has raised $122 million from venture investors to advance
Dive Brief: Biotechnology startup Cardurion Pharmaceuticals on Tuesday raised a $260 million Series B round that will help it build
Vertex Pharmaceuticals’ new treatment for sickle cell disease can eliminate the damaging pain crises people with the blood condition frequently
Dive Brief: An experimental cancer drug developed by Revolution Medicines shrank pancreatic tumors in about one-quarter of participants who had
The popularity of new GLP-1 drugs for weight loss is giving rise to a secondary market with large revenue potential,
Dive Brief: Flagship Pioneering said Wednesday that it’s added another $3.6 billion to its capital base, bringing the total raised
The recent U.S. Supreme Court decision to overturn the Chevron doctrine could open the door to more challenges of Food
Pharmaceutical companies face a looming patent cliff over the next several years, as generic rivals could erode sales of some
Today, a brief rundown of news from Eisai, Spark Therapeutics and Ipsen as well as updates from Element Biosciences and
Dive Brief: The Food and Drug Administration rejected Novo Nordisk’s application to sell a once-weekly insulin treatment called icodec, sending
With tens of billions of dollars at stake, some of the world’s largest drug companies are racing to develop pills
Today, a brief rundown of news from AbbVie and Skyhawk Therapeutics, as well as updates from Arcutis Biotherapeutics and Zevra
Dive Brief: The Federal Trade Commission is preparing to sue the three largest pharmacy benefit managers in the U.S. —
Amylyx Pharmaceuticals achieved what all upstart drugmakers hope to accomplish. In less than 10 years, the Massachusetts-based biotechnology company identified
The Federal Trade Commission on Tuesday released a long-awaited report criticizing the pharmacy benefit manager industry for manipulating the drug
Dive Brief: Biotechnology company HilleVax on Monday said it will halt development of an experimental norovirus vaccine in infants after
Eli Lilly plans to spend $3.2 billion acquiring a Massachusetts-based biotechnology company and its experimental pill for inflammatory bowel disease.
Dive Brief: Two years after canceling an initial public offering, Artiva Biotherapeutics has filed a new proposal centered around plans
Dive Brief: UniQure will sell a gene therapy production plant in Lexington, Massachusetts, to contract manufacturer Genezen in a deal